Altasciences Completes Successful Phase I Trial of Ischemix’ Novel Compound for Treatment of Traumatic Brain Injury (TBI)
Altasciences is pleased to have completed a Phase I trial on Ischemix, Inc.’s novel, proprietary cytoprotective drug candidate, CMX-2043, for the treatment of acute TBI. The trial was performed at Altasciences’ clinical facility in Montréal.
The Phase I trial was performed to evaluate safety, tolerability, and pharmacokinetics in a group of 80 healthy participants in a two-part, double-blind, placebo-controlled study. Single ascending doses (SAD) of CMX-2043 were administered by brief intravenous infusion to 40 male and female participants. Once completed, an additional 40 male and female participants were randomized and received multiple ascending doses (MAD) in the same manner, over five days. The results of the trial showed a well-characterized pharmacokinetic profile, demonstrating dose proportionality over the ranges studied.
“This Phase I trial demonstrates that CMX-2043 has the potential for an excellent safety profile when given intravenously over a wide range of doses,” explained Jerry O. Stern, MD, Chief Medical Officer for Ischemix. “There were no serious adverse events, and all treatment-emergent adverse events were mild and self-limiting. Importantly, the Principal Investigator determined that few adverse events were drug-related.”
There are no TBI-specific therapies approved for the treatment of patients suffering brain injury, yet it is estimated that in the U.S., TBI is responsible for 60,000 deaths per year, and the cause of 80,000 cases of permanent disability.
“It was a pleasure collaborating as the Principal Investigator on this clinical study. We are extremely pleased with the outcome of the CMX-2043 Phase I trial. Having personally witnessed first-hand the outcome that TBI can have on the lives of many people, we hope that the work we are doing with Ischemix will continue to progress. If successful, this treatment could have a tremendous positive impact on the quality of life for TBI patients. That is incredibly rewarding,” stated Dr. Gaetano Morelli, MD, Chief Medical Officer and Principal Investigator for Altasciences. “We wish the team at Ischemix continued success on the next Phase of clinical research.”
Additionally, Co-chief Operating Officer, Marie-Hélène Raigneau, said of the study: “Our goal at Altasciences is to help companies like Ischemix expedite the drug development process without compromising on quality or safety. We are proud to support Ischemix in advancing this vital new therapy.”
Ischemix expects to complete all of the work required for a Phase II trial of CMX-2043 in acute TBI by the end of 2023, and plans to request a pre-IND meeting with FDA for early Q1 2024.
Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster. To learn more about Altasciences, visit altasciences.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
+1 514 601-9763
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AutoTech Breakthrough Recognizes HARMAN As 2023 “Vehicle-to-Everything (V2X) Company Of The Year”4.10.2023 15:00:00 EEST | Press release
HARMAN, an automotive technology company and subsidiary of Samsung Electronics Co., Ltd., today announced it has been selected as “Vehicle-to-Everything (V2X) Company of the Year” in the fourth annual AutoTech Breakthrough Awards conducted by AutoTech Breakthrough, a leading market intelligence organization that recognizes the top companies, technologies and products in the global automotive and transportation technology markets today. The HARMAN Connectivity product lineup, including HARMAN’s latest Telematics Control Unit (TCU), the HARMAN Savari StreetWAVE Roadside Unit (RSU), and the HARMAN Savari MECWAVE edge-based software application platform, is a comprehensive ecosystem of V2X-connected devices and software products that are transforming the connected vehicle segment. The products can be implemented individually or together, ensuring seamless connectivity across vehicles and infrastructure through the combination of PC-5 (short range) and Uu (Cellular) based V2X technologies.
Sims Limited Releases 2023 Sustainability Reporting Suite4.10.2023 15:00:00 EEST | Press release
Sims Limited (ASX:SGM), a global leader in sustainability and an enabler of the circular economy, today announced the publication of its fiscal year 2023 Sustainability Reporting Suite. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231004078890/en/ (Graphic: Business Wire) The company’s annual sustainability reporting suite, which is comprised of a climate report, sustainability report and databook, captures progress against its three sustainability pillars: Operate responsibly Close the loop Partner for change “During the year, the company has made strong performance against our sustainability goals, including early achievement of our 23% reduction in carbon emissions by 2025 target, delivering a 32% reduction on emissions from our FY20 baseline year thanks to an accelerated uptake of renewable electricity across our global operations,” said Stephen Mikkelsen, chief executive officer and managing director at Sims Limited.
Ionblox Debuts Lithium-Silicon Batteries Breaking Barriers of Extreme Fast Charging and Extended Range4.10.2023 15:00:00 EEST | Press release
Ionblox, a leading innovator in battery technology, today announced the launch of its extreme fast charging lithium-silicon cells designed for electric vehicles (EVs). Leveraging the superior energy storage capability of silicon, the company's new cells dramatically reduce charging times while extending driving range, offering EV manufacturers a significant leap in performance and efficiency. The Ionblox technology enables extreme fast charging (XFC), achieving 60% of the battery's capacity in just 5 minutes and 80% in 10 minutes. These advancements make it possible to charge electric vehicles in nearly the same time it takes to fill up a gasoline tank, effectively eliminating one of the key barriers to EV adoption. In addition, Ionblox’s high-energy cells allow EV manufacturers to either extend the range of an EV by 30% to 50% using a similarly sized Ionblox battery pack or to reduce weight and cost with a smaller Ionblox battery pack. "The battery industry has long grappled with the
Dubai International Chamber Strengthens European Presence With Inauguration of New Representative Office in the Netherlands4.10.2023 14:49:00 EEST | Press release
Dubai International Chamber, one of the three chambers operating under the umbrella of Dubai Chambers, has officially launched its fourth European representative office in the Netherlands. The new office was inaugurated yesterday evening during a special ceremony in Amsterdam and is the chamber’s 25th international office worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231004265696/en/ Ribbon-cutting ceremony at the opening of the new Dubai International Chamber representative office in the Netherlands yesterday. From left to right: Noora AlSuwaidi, Regional Director for Europe and the Americas at Dubai Chambers; Wampie Libon, Director of the International Enterprise Department at the Ministry of Foreign Affairs of the Netherlands; Salem Al Shamsi, Vice President of Global Markets at Dubai Chambers; Ali Rashed Alshehhi, Chargé d'Affaires a.i. of the United Arab Emirates to the Kingdom of the Netherlands; Salem M. R
Shippeo Welcomes Julia Overmars as the New Senior Vice President of People, Reinforcing its Commitment to its People4.10.2023 14:03:00 EEST | Press release
Shippeo, the leading supply chain visibility platform, has announced the appointment of Julia Overmars as their new Senior Vice President of People. This strategic role highlights Shippeo's dedication to its employees and the importance of cultivating a people-centric culture within the organization. Julia's extensive experience, international background, and passion for driving human and organizational excellence will make her an invaluable addition to Shippeo's Executive team. Julia brings with her an impressive background, boasting a remarkable 15-year tenure in the field of international Human Resources. Her journey began at Lufthansa Airlines, where she held diverse roles globally, accumulating invaluable insights into HR on a global scale. Following Julia’s time at Lufthansa, she transitioned into the SaaS industry, contributing her expertise to NASDAQ listed technology companies AvePoint and Liveperson, where Julia spearheaded transformative initiatives, particularly in the EMEA
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom